

REMARKS

Claims 24-34 are pending and under consideration. With this Amendment, claims 24 and 32 are being amended. Thus, after entry of this Amendment, claims 24-34 will be pending and under consideration.

Amendments of the Claims

Claims 24 and 32 have been amended as suggested by the Examiner. No new matter is introduced by virtue of the amendments made herein to the claims.

Claim Objections

Claim 24 is objected to because the full terminology has not been provided for the abbreviation "CDRs". Claim 24 has been amended to provide the full terminology for the abbreviation "CDRs", thus the rejection is moot.

Rejection Under 35 U.S.C. § 112, second paragraph

Claims 24-34 are rejected under 35 U.S.C. § 112 as being indefinite. Claim 24 has been amended as suggested by the Examiner, thus the rejection is moot.

Rejection Under 35 U.S.C. § 112, first paragraph

Claims 32-34 have been rejected for lack of enablement. Claim 32 has been amended as suggested by the Examiner, thus the rejection is moot.


No fees beyond those submitted herewith are believed to be due in connection with this Response.

However, the Commissioner is authorized to charge any additional fees that may be required, or credit any overpayment, to Abbott Biotherapeutics Corp. Deposit Account No. 50-4820 (Order No. 116 US PC02)

Respectfully submitted,

Date:

Dec. 16, 2010

A handwritten signature in cursive script, appearing to read "Renee M. Kosslak", written over a horizontal line.

Renee M. Kosslak
Reg. No. 47,717

Abbott Biotherapeutics Corp.
Customer No. 84560
Telephone: 650.454.2338
Facsimile: 650.454.1468